Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.
Moderna announced on Dec. 1, 2021, a revised supply agreement with the UK government for the company’s COVID-19 vaccine and possibly authorized booster vaccine candidates as well. Specifically, this supply agreement encompasses up to 60 million doses of Moderna’s COVID-19 vaccine.
In 2022, as many as 29 million doses are expected to be delivered, and up to 31 million doses are expected to be delivered in 2023. The UK government retains a right to increase or decrease its purchases in 2022 and 2023, under to the agreement, by up to 20% above or below the contracted volumes.
“We thank the UK government for their support in this supply agreement for our mRNA COVID-19 vaccine and booster candidates, if approved, in 2022 and 2023,” said Stéphane Bancel, CEO of Moderna, in a company press release. “This agreement reflects the efforts of the UK government to address the ongoing pandemic and builds on our existing collaboration to protect people in the UK.”
Source: Moderna
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.